cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Ocular Therapeutix Inc
7 own
25 watching
Current Price
$4.32
$0.08
(1.89%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
332.68M
52-Week High
52-Week High
6.525
52-Week Low
52-Week Low
2.57
Average Volume
Average Volume
0.67M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization332.68M
icon52-Week High6.525
icon52-Week Low2.57
iconAverage Volume0.67M
iconDividend Yield--
iconP/E Ratio--
What does the Ocular Therapeutix Inc do?
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the United States. It markets ReSure Sealant, a hydrogel-based ophthalmic wound sealant to seal corneal incisions following cataract surgery. The company's lead product includes DEXTENZA, which is in Phase III clinical trial for the treatment of post-surgical pain and inflammation, allergic conjunctivitis; and in Phase II clinical trial for the treatment of inflammatory dry eye disease. It is also developing OTX-TP, which is in Phase III clinical trial for glaucoma and ocular hypertension. In addition, the company has preclinical development of intravitreal depot with protein-based or small molecule drugs, including tyrosine kinase inhibitors, for the treatment of wet age-related macular degeneration and other retinal diseases. It has a strategic collaboration, option, and license agreement with Regeneron Pharmaceuticals, Inc. for the development of sustained release formulation of the vascular endothelial growth factor trap aflibercept for the treatment of wet age-related macular degeneration and other serious retinal diseases. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.
Read More
How much money does Ocular Therapeutix Inc make?
News & Events about Ocular Therapeutix Inc.
Globe Newswire
30days ago
Dextenza Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6 million, Growing Approximately 14% Over Previous Quarter and Approximately 11% Over Same Quarter of Prior Year Dextenza Net Product Revenue for the Year Ending 2022 is Estimated to be $50.2 million, Representing ...
Business Wire
2 months ago
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences: Jefferies London Healthcare...
Zolmax
3 months ago
Ocular Therapeutix, Inc. (NASDAQ:OCUL Get Rating) major shareholder Summer Road Llc purchased 10,000 shares of the businesss stock in a transaction dated Monday, October 10th. The shares were acquired at an average price of $4.00 per share, for a total transaction of $40,000.00. Following the ...
Ticker Report
3 months ago
StockNews.com upgraded shares of Ocular Therapeutix (NASDAQ:OCUL Get Rating) from a sell rating to a hold rating in a report published on Saturday. Separately, JMP Securities lifted their price objective on shares of Ocular Therapeutix from $20.00 to $25.00 and gave the company a market ...
Frequently Asked Questions
Frequently Asked Questions
What is Ocular Therapeutix Inc share price today?
plus_minus_icon
Can Indians buy Ocular Therapeutix Inc shares?
plus_minus_icon
How can I buy Ocular Therapeutix Inc shares from India?
plus_minus_icon
Can Fractional shares of Ocular Therapeutix Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Ocular Therapeutix Inc stocks?
plus_minus_icon
What is today’s traded volume of Ocular Therapeutix Inc?
plus_minus_icon
What is today’s market capitalisation of Ocular Therapeutix Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Ocular Therapeutix Inc?
plus_minus_icon
What percentage is Ocular Therapeutix Inc down from its 52-Week High?
plus_minus_icon
What percentage is Ocular Therapeutix Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$4.32
$0.08
(1.89%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc.
$8.10
$-0.78 (-8.78 %)
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$3.15
$0.30 (10.53 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.90
$-0.05 (-1.69 %)
Ardelyx Inc
Ardelyx Inc
$3.08
$0.01 (0.33 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc.
$8.10
$-0.78 (-8.78 %)
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$3.15
$0.30 (10.53 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.90
$-0.05 (-1.69 %)
Ardelyx Inc
Ardelyx Inc
$3.08
$0.01 (0.33 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00